Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16953616 | 0.86 | PPARD (0.47) | PPARDL3MBTL1LMNAMAPTATM | |
| SCHEMBL14534817 | 0.83 | GPR3 (0.46) | PPARDPPARAFFAR1FFAR4 | |
| SCHEMBL263354 | 0.81 | L3MBTL1 (0.43) | L3MBTL1NQO1LMNAMAPTATM | |
| SCHEMBL16951200 | 0.81 | L3MBTL1 (0.43) | PPARDL3MBTL1NQO1LMNAMAPT | |
| SCHEMBL16082158 | 0.81 | SCN9A (0.45) | PPARDL3MBTL1NQO1LMNAMAPT | |
| SCHEMBL1911836 | 0.81 | NQO1 (0.54) | NQO1MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL24018251 | 0.81 | GPR3 (0.40) | PPARDL3MBTL1NQO1LMNAMAPT | |
| SCHEMBL16952355 | 0.80 | CA12 (0.47) | PPARDL3MBTL1MAPTALDH1A1KDM4E | |
| SCHEMBL14237315 | 0.79 | L3MBTL1 (0.41) | PPARDL3MBTL1NQO1LMNAMAPT | |
| SCHEMBL16959248 | 0.79 | KDM4E (0.45) | L3MBTL1NQO1LMNAMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493429-B2 | Substituted benzoxazoles and methods of use thereof | GENENTECH, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160009667-A1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2594554-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
| WO-2012008435-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MC2R, NR3C2, REN | PPARD 581/4885L3MBTL1 3290/4885NQO1 2230/4885 |
| US-20160009667-A1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | CYP4X1, BRIX1, HAX1 | PPARD 2360/4885L3MBTL1 4445/4885NQO1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.